



**COLORADO**  
Department of Health Care  
Policy & Financing

Health First Colorado, Colorado Medicaid  
**DUR BOARD MEETING AGENDA**

**November 10, 2020**

**1:00 p.m. – 5:00 p.m. Open Session**

**This will be a virtual attendance-only meeting.**

Virtual meeting Zoom link will be posted at  
<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>  
prior to the meeting.

Health First Colorado, Colorado Medicaid  
**Drug Utilization Review Board**

| <b>DUR Board Members</b>  | <b>CO-DUR Team</b>   |
|---|--|
| Michael Noonan, DO (Chair)<br>Miroslav Anguelov, PharmD<br>Liza Wilson Claus, PharmD<br>Allison Blackmer, PharmD<br>William Lai, PharmD<br>Alison Shmerling, MD, MPH<br>Scott VanEyck, MD<br>Mary Wilkerson, MD | Jeffrey Taylor, PharmD (HCPF)<br>Julia Rawlings, PharmD (CO DUR)<br>Robert L Page II, PharmD, MSPH (CO DUR)<br>Heather Anderson, PhD (CO DUR)<br>Garth Wright, MPH (CO DUR)<br>Gina Moore, PharmD, MBA (CO DUR)<br>Vanessa Patterson, MPH (CO DUR) |

**1. Call to Order and Roll Call**

**2. Introductions and Announcements**

**3. Approval of Minutes from the August 11, 2020 Meeting**

**4. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest:**

- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at [jeffrey.taylor@state.co.us](mailto:jeffrey.taylor@state.co.us) with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.  
[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)





# COLORADO

## Department of Health Care Policy & Financing

### Open Session:

#### 5. Unfinished Business and General Orders:

- Colorado Department of Health Care Policy and Financing Updates
- Retrospective DUR Updates
- Quarterly Module Summary
- FDA Updates
- Quarterly Drug Utilization Reports

#### 6. Updates on Business from Last Meeting:

(Items included in this section are not scheduled for public testimony or board review as part of this agenda)

- Anticonvulsants, Oral
- Stimulants and Related Agents
- Contraceptives, Oral
- Diabetes Management Classes – DPP-4 Inhibitors
- Diabetes Management Classes – GLP-1 Analogues
- Diabetes Management Classes – Hypoglycemic Combos
- Diabetes Management Classes – SGLT-2 Inhibitors
- GI Motility, Chronic
- Anticoagulants
- Colony Stimulating Factors
- Newer Hereditary Angioedema (HAE) Agents
- Mass review drug classes:
  - Bone Resorption Suppression and Related Agents
  - Diabetes Management Classes – Amylin
  - Diabetes Management Classes – Biguanides
  - Diabetes Management Classes – Meglitinides
  - Diabetes Management Classes – TZDs
  - Erythropoiesis Stimulating Agents
  - Prenatal Vitamins
  - Overactive Bladder Agents
  - Ophthalmic Immunomodulators

#### Proposed ProDUR and Prior Authorization Criteria for Other Selected Products:

- ORIAHNN (elagolix, estradiol, norethindrone)
- PALFORZIA (Arachis hypogaea)
- OXYBRYTA (voxelotor)
- OXERVATE (cenegermin-bkbj)
- XERMELO (telotristat ethyl)
- PALYNZIQ (pegvaliase-pqpz)
- QBREXZA (glycopyrronium)

#### Products for Proposed Drug Label Prior Authorization:

- GALAFOLD (migalastat hydrochloride)

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)





# COLORADO

## Department of Health Care Policy & Financing

- Pretomanid
- VIMIZIM (elosulfase alfa)

### 7. New Business (open for public testimony and board review):

#### Proposed Criteria for PDL Drug Classes Scheduled for Review:

- Non-Steroidal Anti-Inflammatories (NSAIDs), Oral
- Non-Steroidal Anti-Inflammatories (NSAIDs), Non-Oral
- Antibiotics, Inhaled
- Hepatitis C Virus Treatments - Direct-Acting Antivirals (DAAs)
- Pulmonary Arterial Hypertension (PAH) Agents
  - Phosphodiesterase Inhibitors (PDEIs)
  - Endothelial Antagonists
  - Prostanoids
  - Guanylate Cyclase Stimulators
- Triptans and other Migraine Treatments, Oral & Non-Oral
- Antipsoriatics, Oral
- Antipsoriatics, Topical
- Antiemetics
- *H. Pylori* Treatments
- Methotrexate Products
- Targeted Immune Modulators (TIMs)
- **Antihyperuricemics**
- **Mass review drug classes\*:**
  - Antiherpetic Agents, Oral and Topical
  - Fluoroquinolones, Oral
  - Hepatitis C Virus Treatments – Ribavirin Products
  - Newer Generation Antidepressants
  - Monoamine Oxidase Inhibitors (MAOIs)
  - Tricyclic Antidepressants (TCAs)
  - Pancreatic Enzymes
  - Proton Pump Inhibitors
  - Non-Biologic Ulcerative Colitis Agents, Oral & Rectal
  - Antiplatelet Agents
  - Epinephrine (self-administered) Products

*\*Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated*

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.  
[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)





# COLORADO

## Department of Health Care Policy & Financing

*classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

### Proposed ProDUR and Prior Authorization Criteria for Other Selected Products:

- **EVRYSDI** (risdiplam)
- **XYWAV** (calcium, magnesium, potassium, sodium oxybates)
- **ENSPRYNG** (satralizumab-mwge)
- **JYNARQUE** (tolvaptan)
- **UPLIZNA** (inebilizumab)
- **VILTEPSO** (viltolarsen)
- **LAMPIT** (nifurtimox)
- **BYNFEZIA** (octreotide acetate)
- **HEMADY** (dexamethasone)

### 8. Adjournment

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at [jeffrey.taylor@state.co.us](mailto:jeffrey.taylor@state.co.us) or the 504/ADA Coordinator [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

